Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma

Journal of the American Animal Hospital Association
Sílvia Regina Ricci LucasDiana Helena De Benedetto Pozzi

Abstract

A chemotherapeutic protocol using carmustine in combination with vincristine and prednisone was tested in dogs with multicentric malignant lymphosarcoma. Of seven dogs treated, six (85.7%) achieved complete remission. A partial response occurred in one dog. Median survival time was 224 days (mean 386 days), and median duration of remission was 183 days (mean 323 days). Marked neutropenia was observed following carmustine administration. There were no significant alterations in platelets and red blood cell counts during treatment, and no abnormalities attributable to the chemotherapy were found in serum biochemical profiles. Results of this study showed that carmustine is an effective alternative option in the treatment of canine lymphosarcoma.

References

Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E TeskeW Misdorp
Aug 1, 1990·Cancer·P G GreenleeP H Lieberman
Dec 1, 1982·Cancer Treatment Reviews·R B Weiss, B F Issell
Jan 1, 1996·The Veterinary Clinics of North America. Small Animal Practice·R C Rosenthal
Feb 21, 1998·Journal of Veterinary Internal Medicine·N C MyersS M Cotter
Sep 5, 1998·Journal of the American Animal Hospital Association·C A WoodW M Rand
Nov 24, 1998·Journal of the American Animal Hospital Association·J CrawshawR A Henderson
Apr 20, 2000·Journal of Veterinary Internal Medicine·R ChunD M Vail
Sep 21, 2000·Journal of the American Animal Hospital Association·K L Boyce, B E Kitchell

❮ Previous
Next ❯

Citations

Mar 1, 2006·Veterinary and Comparative Oncology·A K LeBlancJ W Bartges
Mar 28, 2008·Veterinary Clinical Pathology·Alexandre MerloSílvia Regina Ricci Lucas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.